Skip to main content
Caplight Logo









Elogium Probiotics

Elogium Probiotics

Private
RigaHealthcare & Life Scienceshttp://elogium.bio/

Last Round

Grant

Jun 26, 2025

Total Funding Raised

$594,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Elogium Probiotics is a biotechnology company that develops a probiotic feed additive for the poultry industry designed to combat pathogens and improve growth.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Compliance

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts

AI Layer

Non-AI

Keywords

probiotic feed additiveanimal healthfood safetyantibiotic alternativepathogen controlpoultry probioticsagritechagtechnatural growth promoterBacillus subtilisanimal nutritionCampylobacter reductionSalmonella reductionlivestock feed additivefeed conversion ratioswine probiotics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elogium Probiotics Comparables

Compare Elogium Probiotics with similar companies based on industry and business-model similarity.

Elogium Probiotics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Akeso Biomedical, Inc.
82%
General Probiotics
78%
Proteon Pharmaceuticals
78%

Elogium Probiotics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 26, 2025
SeedFeb 16, 2023
Pre SeedSep 10, 2021

Key People

Founding team and executive leadership

Katarina Šimunović

Chief Technology Officer And Co-founder

Founding Team

Karlis Udris

Chief Executive Officer, Co-Founder

Founding Team

Elogium Probiotics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors grew 107% MoM, reaching 2.3K.

  • May 16, 2026

    Monthly visitors increased 34% MoM.

Elogium Probiotics Filings

Explore SEC and related filing metadata, where available.

Elogium Probiotics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Elogium Probiotics's valuation, stock price, and market status.

Is Elogium Probiotics a public or private company?

Elogium Probiotics is a private company.

What is the current stock price of Elogium Probiotics?

Elogium Probiotics is a private company with no public stock price. No recent secondary market data is available.

How much is Elogium Probiotics worth (valuation)?

Valuation information for Elogium Probiotics is not publicly available.

Can I buy Elogium Probiotics stock?

Elogium Probiotics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Elogium Probiotics's last funding round?

Elogium Probiotics's most recent funding round was Grant on June 26, 2025.

Who are the main investors in Elogium Probiotics?

Key investors in Elogium Probiotics include Commercialization Reactor.

Will Elogium Probiotics IPO soon?

No public IPO plans have been announced for Elogium Probiotics.

How can I track Elogium Probiotics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Elogium Probiotics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersRiga
Employee Range4
Year Founded2021
Last FundingJun 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?